SAREPTA THERAPEUTICS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
SAREPTA THERAPEUTICS, INC. (SRPT) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $92.35 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2024-11-06
- 2024-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $92.35M.
- 2024-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $99.54M.
- 2023-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $794.00K.
- 2023-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2024-09-30 | $92.35M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $99.54M 10-Q · filed 2024-08-07 |
| 2023-09-30 | $794.00K 10-Q · filed 2023-11-01 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-02 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-02 |
| 2017-09-30 | $2.91M 10-Q · filed 2017-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |